These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
The robotic surgery program has continually pushed the boundaries of medical technology
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
This project is supported by the Irish Government through IDA Ireland
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Subscribe To Our Newsletter & Stay Updated
